Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized confirm trial

  1. Leo, A.D.
  2. Jerusalem, G.
  3. Petruzelka, L.
  4. Torres, R.
  5. Bondarenko, I.N.
  6. Khasanov, R.
  7. Verhoeven, D.
  8. Pedrini, J.L.
  9. Smirnova, I.
  10. Lichinitser, M.R.
  11. Pendergrass, K.
  12. Malorni, L.
  13. Garnett, S.
  14. Rukazenkov, Y.
  15. Martin, M.
Aldizkaria:
Journal of the National Cancer Institute

ISSN: 1460-2105,  0027-8874

Argitalpen urtea: 2014

Alea: 106

Zenbakia: 1

Mota: Artikulua

DOI: 10.1093/JNCI/DJT337 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus